modernaAnalysis
Moderna Shares Plunge 25% Following Cancer Vaccine Data Leak
Moderna shares fell 25% following an accidental data leak of its cancer vaccine trial with Merck, despite positive results showing a 42% reduction in melanoma recurrence or death when combined with Keytruda.